WebBackground: Spiromax(®) is a novel dry powder inhaler for patients with asthma or chronic obstructive pulmonary disease (COPD). The studies presented here provide further data … WebFor DuoResp Spiromax® 160micrograms/ 4.5micrograms Asthma, maintenance therapy for DuoResp Spiromax® 160micrograms/ 4.5micrograms By inhalation of powder. Child 12–17 years Initially 1–2 inhalations twice daily; reduced to 1 inhalation daily, dose reduced only if control is maintained.
Budesonide with formoterol Drugs BNF NICE
WebObjective: Adherence and inhaler technique are often suboptimal in asthma and chronic obstructive pulmonary disease (COPD). New inhalers have been developed to improve these determinants of treatment effectiveness. We assessed treatment adherence, satisfaction, and ease of use of DuoResp ® Spiromax ® among SPRINT study … WebBackground: Spiromax(®) is a novel dry powder inhaler for patients with asthma or chronic obstructive pulmonary disease (COPD). The studies presented here provide further data on attributes (in vitro dosing consistency with budesonide-formoterol (DuoResp) Spiromax; flow rates through empty versions of the Spiromax and Turbuhaler inhaler) of importance to … firestone chesapeake va
DuoResp Spiromax (budesonide / formoterol - European …
WebThe two active substances in DuoResp Spiromax are well known and ar e present in several medicines used to treat asthma and COPD, either alone or in combination with … WebApr 1, 2024 · Informationen zum Medikament DuoResp® Spiromax® 160 Mikrogramm/4,5 Mikrogramm Pulver zur Inhalation von TEVA GmbH mit Wirkstoff Budesonid, … WebDuoResp Spiromax is indicated in adults (18 years and older) for the treatment of asthma, to achieve overall asthma control, including the relief of symptoms and the reduction of the risk and exacerbations (see Section 4.2 Dose and method of administration). DuoResp Spiromax is not indicated in children and adolescents under the age of 18 years as ethyl silicate binder